Home › Therapeutic areas › Oncology › Cholangiocarcinoma

Cholangiocarcinoma (10 companies)

Companies with an active program in Cholangiocarcinoma.

Ticker Company Therapeutic areas Programs Lead stage Mkt cap Programs
CMPX Compass Therapeutics Oncology 1 Phase 2 $109M 15
CGEN Compugen Oncology 1 Phase 3 $191M 7
CBIO Crescent Biopharma Oncology 1 Phase 2 $507M 10
CTMX CytomX Therapeutics Oncology 1 Phase 1 $423M 7
NBP NovaBridge Biosciences OncologyOphthalmology 1 Phase 2 $95.4M 7
RLAY Relay Therapeutics DermatologyOncology Rare 1 Approved $3.64B 4
REPL Replimune Group Oncology 1 Approved $1.87B 5
SMMT Summit Therapeutics Oncology 1 NDA Submitted $8.53B 6
TYRA Tyra Biosciences MetabolicOncology Rare 1 Phase 2 $1.35B 5
ZYME Zymeworks OncologyRespiratory 1 Approved $1.78B 12